University of Washington psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
University of Washington is listed with 7 registered studies counted here, in Seattle, United States. By compound: 6 psilocybin and 1 MDMA. By registry status: 1 not yet recruiting, 3 active, not recruiting and 3 completed. By phase: 1 early phase 1, 2 phase 1, 3 phase 2 and 1 phase 3. Reported start years run from 2022 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 7 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 6 |
| MDMA | 1 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Not yet recruiting | 1 | 14% |
| Active, not recruiting | 3 | 43% |
| Completed | 3 | 43% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 14% |
| Phase 1 | 2 | 29% |
| Phase 2 | 3 | 43% |
| Phase 3 | 1 | 14% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression | NCT07565909 | Not yet recruiting | Phase 2 | 2026-06-01 | Psilocybin |
| Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | NCT07336238 | Active, not recruiting | Phase 2 | 2026-04-01 | Psilocybin |
| Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) | NCT06853912 | Active, not recruiting | Phase 2 | 2025-06-01 | Psilocybin |
| A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | NCT06644170 | Completed | Phase 1 | 2024-11-19 | Psilocybin |
| MDMA-Assisted Therapy for Pathological Narcissism | NCT06565494 | Active, not recruiting | Early Phase 1 | 2024-08-27 | MDMA |
| Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | NCT05847686 | Completed | Phase 1 | 2023-06-27 | Psilocybin |
| Frontline Clinician Psilocybin Study | NCT05163496 | Completed | Phase 3 | 2022-03-03 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.